Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02123758 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 110 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. New version filed on ClinicalTrials.gov
  2. 20 versions Re-verified since Dec 5, 2024, no change to tracked fieldsv90-v109
  3. Primary completion date: Jun 2016 to Jun 27, 2016
    • Study completion date: Dec 2027 to Dec 31, 2027
    • Start date: Jul 2014 to Jul 9, 2014
    v89
  4. Primary completion date: Jun 27, 2016 to Jun 2016
    • Study completion date: Dec 31, 2024 to Dec 2027
    • Start date: Jul 9, 2014 to Jul 2014
    v88
  5. 13 versions Re-verified since Sep 12, 2023, no change to tracked fieldsv75-v87
Show 14 earlier versionsHide 14 earlier versions
  1. Primary completion date: Jun 2016 to Jun 27, 2016
    • Study completion date: Oct 2023 to Dec 31, 2024
    • Start date: Jul 2014 to Jul 9, 2014
    v74
  2. 6 versions Re-verified since Feb 14, 2023, no change to tracked fieldsv68-v73
  3. Primary completion date: Jun 27, 2016 to Jun 2016
    • Study completion date: Oct 15, 2022 to Oct 2023
    • Start date: Jul 9, 2014 to Jul 2014
    v67
  4. 6 versions Re-verified since May 19, 2022, no change to tracked fieldsv61-v66
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.
Trial Details
NCT Number NCT02123758
Lead Sponsor Aragon Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 57 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov